|
APLF expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.23399998289642E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.41060000347082E-08 |
| Normal-vs-Stage2 |
3.953700E-04 |
| Normal-vs-Stage3 |
4.65939997695841E-09 |
| Normal-vs-Stage4 |
2.81739999996589E-06 |
| Stage1-vs-Stage2 |
6.936800E-01 |
| Stage1-vs-Stage3 |
3.019800E-01 |
| Stage1-vs-Stage4 |
5.463000E-01 |
| Stage2-vs-Stage3 |
8.856400E-01 |
| Stage2-vs-Stage4 |
9.426800E-01 |
| Stage3-vs-Stage4 |
9.318200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.6536000042916E-09 |
| Normal-vs-AfricanAmerican |
2.50180000005429E-06 |
| Normal-vs-Asian |
4.638000E-04 |
| Caucasian-vs-AfricanAmerican |
3.004400E-01 |
| Caucasian-vs-Asian |
5.933200E-01 |
| AfricanAmerican-vs-Asian |
2.026400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.60490000000735E-06 |
| Normal-vs-Female |
3.20280024723729E-10 |
| Male-vs-Female |
4.181800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.99379999996385E-06 |
| Normal-vs-Age(41-60Yrs) |
7.50440043439937E-10 |
| Normal-vs-Age(61-80Yrs) |
1.73430003691522E-09 |
| Normal-vs-Age(81-100Yrs) |
8.763400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.090990E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.452400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.416200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.895200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.622400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.466000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.279800E-01 |
| Classical-VS-Follicular |
1.351390E-04 |
| Classical-VS-Other |
6.719600E-01 |
| Classical-VS-Normal |
8.00150000035416E-07 |
| Tall-VS-Follicular |
9.840500E-02 |
| Tall-VS-Other |
5.261200E-01 |
| Tall-VS-Normal |
3.96900000000366E-05 |
| Follicular-VS-Other |
2.739600E-01 |
| Follicular-VS-Normal |
2.55440113505756E-11 |
| Other-VS-Normal |
5.828400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.23440180089096E-11 |
| Normal-vs-N1 |
3.04019999997074E-06 |
| N0-vs-N1 |
7.762400E-01 |
|
|
